- LOGIN
- MemberShip
- 2026-04-17 15:11:30
- Policy
- Generic exclusivity for ₩50 million Betmiga applied
- by Lee, Tak-Sun Jan 13, 2020 06:26am
- The first generic drug of 'Betmiga' (Mirabegron, Astellas), a potent overactive bladder treatment, coming soon in June this year applied for permission. The interest in the industry is amplified because generic exclusivity are given exclusive rights to the generic market based on who first applied for the permit. According to the MFDS and the industry on the 10th, the application for permission of the Betmiga was received on Dec 31. Since the re-examination period for the Betmiga was expired on Dec 30, the application for authorization was submitted the next day, Dec 31. However, the number of licensed items and company names have not been disclosed yet. Currently, 11 Korean companies have established the basis for early entry into the market, excluding the material patents of Betmiga, winning the decision to invalidate crystalline invalid patents. Accordingly, the first applicant of the 11 companies is likely to obtain a generic exclusivity, which is granted generic market monopoly for nine months. The 11 companies are Hanmi pharmaceutical, Chong Kun Dang, JW pharmaceutical corporation, Daewoong Pharmaceutical, Ildong Pharmaceutical, Intro biopharma, Alvogen Korea, Kyungdong pharmacetical, Shinil Pharm Ltd, Hanwha Pharma Co., LTD, and Shin Poong Pharm. Co., LTD. However, all 11 companies did not submit the application for permission last month. Some companies have reportedly failed to demonstrate bioequivalence with the original drug. As such, only a few companies are likely to win generic exclusivity. Generic exclusivity is expected to be granted for nine months from the day after May 3, 2020, when the Betmiga’s patent expires. During this period, the same ingredient generics will not be released, so it is highly likely that the rights holder will preoccupy the market. Accordingly, companies that have acquired generic exclusivity are expected to conduct aggressive marketing and marketing during that period. Betmiga is a large item of about ₩50 billion per year. In 2020, it is expected that Betmiga’s generics will struggle over the market.
- Company
- Hana secured copyright for anesthetic drugs in 6 countries
- by Lee, Seok-Jun Jan 13, 2020 06:26am
- Hana Pharm Co. announced on the 9th that it signed an exclusive contract with six countries in Southeast Asia for anesthetic drug, Remimazolam. Remimazolam is a new anesthetic drug that is considered to be a Propofol alternative. After finishing phases III in each country, they are getting global approval for Japan, USA and Europe. The original developer is Paion by Germany, and Hana has acquired the rights of six Southeast Asian countries following Korea. According to the disclosure, Southeast Asian countries are Vietnam, Indonesia, Thailand, Philippines, Singapore and Malaysia. The other party is Paion and the contract is €1.5 million (about ₩2 billion). Phased permits, launches, and sales-linked milestones will be paid separately. Remimazolam has a global license ahead. Depending on the country partner, Japan's Mundipharma issued a permit application in December 2018, Cosmo Pharmaceutical U.S.A., 2019, and European Paion in November. In Korea, Hana completed the application for approval on December 30 last year. It is likely to be the first to be approved in Japan. If the permit is granted, it will have a positive effect on domestic approval. OEM Europe and Japan Export Challenge Hana is setting export targets for Europe and Japan in addition to the Remimazolam copyright contract. The region plans to advance to Paion's 2nd Vendor OEM. There are only four Remimazolam producers in the world, including Hana. Hana's strategy is to establish a global market base through Southeast Asian copyright and European and Japanese consignment production. Hana is also expanding its facilities to meet the demand for Remimazolam. Hana decided to invest ₩58.5 billion in November to construct a new injection plant and introduce facilities. The new plant's production capacity is estimated at ₩200 billion for injection. Operation is expected in 2022. In last February, the facility invested. In order to secure the site for the new factory, the company purchased the sale of the Pyeongtaek Dreamtech General Industrial Complex. Kepa has not been decided yet, but the new plant will be completed by 2025. An official of the company explained, "Remimazolam can be produced in existing factories, but is investing in facilities to meet the growing demand".
- Policy
- Certican price reduced by ATP to KRW 5250 for 1mg
- by Kim, Jung-Ju Jan 13, 2020 06:22am
- The price of Novartis’ immunosuppressant Certican (everolimus) was lowered on Jan. 9, as a result of the recent actual transaction price (ATP) survey on reimbursed drugs. The price could be further adjusted when the final decision is made from the administrative litigation between the company and government about ex-officio adjustment of the drug pricing. On Jan. 8, Korea’s Ministry of Health and Welfare (MOHW) has issued the partially revised ‘List of Reimbursed Drugs and Maximum Reimbursement Price’ reflecting the price change. Last year, the government surveyed ATP of drugs supplied to healthcare institutes to calculate weighted average value, and lowered maximum reimbursed price of each drug item by no more than ten percent according to the survey result and calculation. Currently, Certican is in the midst of administrative litigation against the government’s decision to lower the drug pricing by 30 percent due to a first generic listing, but the company has requested for suspension on enforcement of the ex-officio adjustment. If the request had not been accepted by the court, the drug pricing would have been lowered by more than the ATP-based price reduction rate, which would not have been reflected. While the company is maintaining the original pricing with last year’s adjustment is suspended by the prolonged litigation, the government had to lower Certican’s pricing by ATP-based reduction rate like any other drugs. Accordingly, the new reimbursed maximum prices of Certican in different doses are 2,266 won for 0.25 mg, 3,617 won for 0.5 mg, 4,450 won for 0.75 mg and 5,250 won for 1.0 mg.
- Company
- Sanofi recruits 4943 patients in three clinical trials
- by Chon, Seung-Hyun Jan 13, 2020 06:22am
- Hanmi Pharmaceutical's new technology, "Efpeglenatide", exported to Sanofi, continues commercializing smoothly.. Three cases were recruited out of five phase III trials. In three clinical trials, a total of 4943 patients were recruited, accumulating the scientific evidence to prove the competitiveness of Efpeglenatide. The whole view of Hanmi Pharmaceutical HeadquartersAccording to Clinical Trials, a clinical information site run by the National Institutes of Health (NIH), Sanofi recently completed a recruitment of one of the Phase III trials of Efpeglenatide. This is a Phase III clinical trial comparing the combination of Efpeglenatide and Metformin with the competing drug Trulicity ( Dulaglutide). Sanofi began the trial in September 2018 and after enrolling 481 subjects, changed the clinical stage to “Active, not recruiting” on the 7th.. The target completion date is next February. Sanofi has completed three of the five trials of Efpeglenatide in Phase III trials. Efpeglenatide is a GLP-1-based diabetic drug that extends daily injections from once a week to up to once a month. It is based on Hanmi’s 'Lapscovery' technology. Lapscovery is a platform technology that increases the short half-life of biopharmaceuticals and reduces the number of doses and dosages to reduce side effects and improve efficacy. Hanmi signed a technical export contract with Sanofi’s Efpeglenatide in November 2015, and holds the record of the largest contract ever for four years. In November 2015, Hanmi signed a contract with Sanofi to export technology for a total of €3.9 billion in quantum projects (Efpeglenatide·sustained insulin· Efpeglenatide·sustained insulin). The down payment is €400 million. In December 2016, Hanmi signed an amendment agreement with Sanofi to return one of its technology transfer projects. Hanmi returned €196 million to Sanofi out of the €400 million received from Sanofi. Sanofi announced a detailed development plan at the end of 2017, two years after taking the rights of Efpeglenatide. Sanofi began five clinical trials in late 2017 after the first phase III trial comparing Efpeglenatide to placebo. In last June, 4076 people were enrolled in the AMPLITUDE-O, which is considered the core clinical trial of Efpeglenatide. In last October, the recruitment of AMPLITUDE-M compared to placebo was completed. A total of 4943 patients were enrolled in the three clinical trials that were completed. It is accumulating scientific evidence to secure market competitiveness while demonstrating the safety and effectiveness of Efpeglenatide in large patients. Efpeglenatide survived the reorganization of Sanofi's harsh R&D pipeline. Efpeglenatide is the only diabetic drug among the five R&D pipelines that Sanofi has set for NDA within two years. Sanofi suddenly stopped developing GLP-1 based triple agents (SAR441255) last year. It also returned the rights of the SGLT-1/2 double inhibitor ‘Zynquista(Sotagliflozin)’, which was introduced in 2015. Sanofi announced in last December that Sanofi increased its investment in four areas: cancer, blood disease, rare disease, and nervous system disease and stopped research into cardiovascular disease. Efpeglenatide is in a position to complete development and search for a new vendor.
- Policy
- More rare diseases designated for special case NHI benefit
- by Lee, Hye-Kyung Jan 13, 2020 06:22am
- From Jan. 1 this year, the government expanded list of designated rare diseases and healthcare institutes examining rare disease eligible for the special case healthcare benefit. To reduce medical expense and to improve medical access for patients with ultra rare and unknown diseases, National Health Insurance Service (NHIS, President Kim Yong-ik) announced the extended list of rare disease and healthcare institute examining rare disease for special case National Health Insurance (NHI) benefit that came in effect from Jan. 1. The objective of the special case benefit system is to reduce patient’s copayment rate on expensive rare and severe disease treatment, which makes a rare disease patient to be responsible for 10 percent of inpatient and outpatient medical expense. Accordingly, the list of designated rare disease receiving special case benefit has been expanded to include 1,014 rare diseases, applying the benefit to around 270,000 patients. Before the change, it used to be approximately 265,000 patients receiving the benefit. Constantly listening to patients, their family, patient groups and related academic societies, NHIS increased the number of designated rare disease for the benefit after a series of deliberation by Rare Disease Management Committee (Korea Centers for Disease Control and Prevention) and Special Case Benefit Committee (NHIS). From last year, the government agency has opened a separate disease group dedicated for unspecified chromosome abnormalities, as patients with the condition could not receive any special benefit without a specific name of diagnosed disease. Rare disease patients with the designated special case disease are expected to access treatment with lessened financial burden, as supported by special case NHI benefit and Rare Disease Patient Medical Aid program. Also the NHIS has added more healthcare institutes to examine and diagnose rare disease. Since 2016, NHIS has appointed qualified healthcare institute to exam ultra rare disease and unspecified chromosome abnormalities to promptly but accurately provide special case benefit to the patients. In December, the agency called for a bidder among tertiary hospitals offering rare disease or genetics clinic, and selected seven more hospitals, making total of 28 hospitals available for rare disease examination from this year. The new appointment was to expedite examination procedure to diagnose increasing number of rare disease eligible for NHI special case benefit, and to resolve inconvenience of patients in regions without the designated institute, such as Jeonnam, Jeonbuk and Chungbuk. A NHIS official stated, “The agency would continue to improve rare disease patient’s access to treatment by providing special case benefit to growing number of newly diagnosed rare diseases found with fast-advancing technology, and by appointing more healthcare institutes capable of examining the diseases for the patients to receive adequate treatment.”
- Company
- “RSA expansion, a foundation to expedite new drug listing"
- by Eo, Yun-Ho Jan 10, 2020 06:26am
- A ‘new drug’ holds the foremost value of the pharmaceutical industry. And global pharmaceutical companies’ eyes are currently fixated on the ‘adequate value of new drug’ than ever before. As the era of high-cost drug has come, government and pharmaceutical industry’s gap in views of drug pricing has never been so apart. Korea Research-based Pharmaceutical Industry Association (KRPIA), representing the voices of global pharmaceutical companies in Korea, is stepping forward seeking the middle ground of the two. A consensus between them does exist. For an instance in last year, the Korean health authority expanded scope for risk sharing agreement (RSA) and announced a plan to apply RSA on follow-on drug and to expand pharmacoeconomic evaluation (PE) exemption system. The year 2020, the time of changes and expectations, marks Chair Avi Benshoshan’s third year serving KRPIA. And Daily Pharm interviewed him for this year’s plan of the organization. Chair Avi Benshoshan#- New Year’s greetings and message for the member companies. As you may be aware, this year would be another year of economic recession and sluggish growth as predicted by major economic indicators. However, we hope to create a regulatory environment that recognizes value of innovation to maintain the growth engine of pharmaceutical and bio industry this year as well. And I wish everyone has a year full of keen wisdom to seek an opportunity in crisis, like a small but bright mouse. - KRPIA member companies share a common theme of ‘new drug.’ But each of them has diverse field of expertise in anticancer, rare disease, chronic disease and off-patent treatments, which comes with different interest groups. Respective member companies have their own specialized field, but in a bigger frame, they are all heading for the same goal of improving patient’s health. In the same sense, KRPIA is planning to present more concrete basis for new drug to strengthen the ‘patient-centered healthcare policy,’ and to reinforce the organization’s role as a communicator between government and healthcare sector stakeholders. The organization ultimately aims for a mutual growth through raising awareness of social value in new drug and improving policy. We think the government, global pharmaceutical companies and the organization also share a same goal of adequately providing new drug to patients in urgent need and lowering barrier of new drug access to prevent disheartening catastrophe of patients giving up on treatment for financial reasons. - It could be considered quite limited, but the organization’s long-awaited drug pricing system revision is in process. The organization sees it as a positive change as RSA scope expansion and PE-exemption system amendment are all part of regulatory reform to improve patient’s access to new drug. We fully understand the government’s contemplation on soaring medical expense. However, considering on how ‘Korea Passing’ phenomenon was a prevalent issue throughout the pharmaceutical industry, decision on new drug reimbursement has reached a difficult point in time as it has to take account of other countries as well. We have a great anticipation on the government’s decision to expand scope of RSA as it was their solution balancing between stable National Health Insurance (NHI) finance and patient’s access to new drug. And also it could be a starting point of regulatory reform to adopt fast-track listing. Although the government has not unveiled any specifics, yet, the organization plans to cooperate with the government to deliver the complete effect of regulatory change to the patients. -Last year, the government presented a research outcome on new drug review period. What do you suggest is needed to enhance the review system? The last year’s research holds a significant meaning to it as it investigated, for the first time in Korea, the actual time taken for new drugs to be reviewed and approved in Korea.” The average time taken for review and approval on 115 investigational new drugs in Korea was approximately 300 days, similar to that in other advanced countries. Unlike other countries with already set predictability of the review system, however, Korea’s approval period showed large gaps between different items and in different years. Predictability is a crucial factor for a business, therefore, the government should consider including additional supplementary material submission period as part of the review processing period to raise regulatory predictability like the other countries. And for rare disease treatment with urgent and highly unmet medical need, the government should activate preferential review system, differentiated from general approval procedure and implement practical policies for better effectiveness. - Regarding regulations, in which part does KRPIA try to improve or recommend? To enhance Korea’s medical and bio companies’ capacity and support their global market expansion, KRPIA has been operating ‘Global Pharmaceutical Company-Startup Co-incubating Platform’ with KOTRA since March 2018, targeting about 100 medical and bio startups. And in 2019, we have organized ‘Global Open Innovation Korea’ with KOTRA, Ministry of SMEs and Startups and Korea Institute of Startups & Entrepreneurship Development (KISED) as an effort to meet the government’s biohealth industry fostering policy. We highly appreciate the government's commitment designating the biohealth industry as one of top key emerging industries and also their aggressive investment on the industry. Nevertheless, it is unfortunate to see multiple government bodies executing different biohealth industry fostering policies resulting in overlapped actions and inefficient communication in between the policies. Based on other cases in overseas, the massive scale of government’s investment, determined to assertively support the bio industry, is as important, but also we believe focusing investment efficiently among various government policies would bring a success to the policy. As Korea already has an outstanding infrastructure in basic science, life science and clinical study for development of biohealth industry, it would be wise to fine tune policies between government bodies to maximize the investment effect. –How about a word of determination and ambition for the New Year’s? For the year 2020, KRPIA plans to provide even more concrete basis for new drug to strengthen ‘patient-centered healthcare policy’, and to raise awareness of social value in new drug. Also, the organization would engage with government and healthcare sector interest groups better to improve existing policies. And we would endeavor to grow deeper mutual relationship between Korean and global pharmaceutical companies in various fields like technology co-development and overseas market co-marketing. Last but not least, the organization would fully support Korea to become a pharmaceutical powerhouse by hosting more clinical trials and increasing R&D investment. We hope the pharmaceutical industry could bring better health to the people and result in fruitful outcome to contribute improving the people’s happiness.
- Policy
- Choline alfoscerates, 82 generics were approved last year
- by Lee, Tak-Sun Jan 10, 2020 06:26am
- The most representative of choline alfosceratesDespite the controversy over last year's efficacy, choline alfoscerate formulations were found to have received 82 new licenses last year. Only 267 cumulative licensed items are available. On the 9th of last year, an investigation into the approved items of the same ingredient was conducted through MFDS' website. The choline alfoscerate formulation was found to have a validity issue during a national audit last October. In response, the Ministry of Health and Welfare announced plans to conduct a pay reevaluation by June this year, and the MFDS began validating in November. The industry believes that choline alfoscerate's reimbursement restrictions are strong. Nevertheless, pharmaceutical companies considered the high marketability of the formulation and continued to produce the product. Choline alfoscerate formulations form a large market with insurance claims amounting to about ₩300 billion. Irrespective of the size of hospitals and majors, the elderly are indiscriminately prescribed for the prevention of dementia. It is a perfect market for domestic pharmaceutical companies that do generic sales in the parliamentary market. In addition, consignment items poured out last year as new formulations such as liquid In hard capsules and syrups, which can be bottled, were released. Choline alfoscerate formulations, despite no original patent expiration issues last year, recorded a number of licensed items following Pregabalin (93) and Oseltamivir (87). Major generic drug licenses in 2019 Pregabalin and Oseltamivir formulations have recently expired. However, Pregabalin has three doses, and Oseltamivir is difficult to make an indirect comparison in that there are three capsule dosage forms and a suspension formulation. The MFDS is currently validating Choline alfoscerate preparations, but it is difficult to draw conclusions. Since it has already been validated through the 2018 update, it is difficult to conduct clinical reevaluation due to lack of literature data. However, the industry reports that reimbursement revaluation may result in reimbursement restrictions in order to reduce consumption.
- Company
- The controversy of Eliquis' fluctuating price
- by Jung, Hye-Jin Jan 10, 2020 06:25am
- The price of Eliquis, an anticoagulant drug, Apixaban, has fluctuated several times. Wholesalers and pharmacies dealing with dispensing and distribution are also confused. In particular, as the most recent provisional disposal application that Korea BMS applied for was accepted earlier than expected, some pharmacies and wholesalers had to pay the difference, but Korea BMS showed a negative attitude toward settlement. Initially, the Ministry of Health and Welfare announced that as of January 1 this year, the Eliquis insurance price, which is ₩1185, will be reduced to ₩830 , a 30% reduction. Accordingly, Korea BMS has proceeded with the original lawsuit to prevent the price cut, and has defended the price cut right now by applying for suspension of execution. The BMS filed an application for disposition shortly after the suspension of drug price reduction was lifted after the first trial decision by the Ministry of Health and Welfare. As the court accepted it, the drug price, which was lowered on January 1, recovered to ₩1185 from two days later. The problem is that the provisional decision was unexpectedly fast and was shipped at a reduced price on the first two days of January. There was no time for wholesalers and pharmacies to cope. January 1 2020 was a public holiday, but during the two-day weekday, wholesalers and pharmacies nationwide charged Eliquis at ₩830. Even though pharmaceutical companies need to settle balances on shipments made during the day, Korea BMS has been controversial, stating that it will only settle for prescription quantities. Personal information such as the patient's prescription is required to check the quantity of the prescription. But, wholesalers or pharmacies cannot provide the personal information to pharmaceutical companies under the Personal Information Protection Act. A wholesaler said, “As the result of the application for disposable treatment on the afternoon of January 3, we had a hard time reprocessing all the shipments that were shipped on the morning of the day at the original medicine price, and if a drug company wants to settle the balance only for the prescription of a hospital, it is like evading settlement”. The official pointed out that BMS is the first Korean pharmaceutical company to announce such a settlement method. A BMS official explained, “The company anticipates the problems that may arise as the price of medicines has been reduced, and has countermeasures, and will confirm the specific details and answer”.
- Policy
- 23 new drugs approved last year with no Korean-made
- by Lee, Tak-Sun Jan 10, 2020 06:25am
- Apparently, total 23 investigational new drugs have been approved in Korea last year. Compared to 2018, the number was increased by 14 but not one of them was made in Korea. Moreover, two incrementally modified drugs (IMDs) and three biosimilars have been cleared. According to Ministry of Food and Drug Safety (MFDS)’s pharmaceutical information website on Jan. 8, updated information of newly approved investigational drugs in 2019 found that total 23 drugs have been passed by MFDS last year. All of them were developed outside of Korea. Korean pharmaceutical companies JW Pharmaceutical, Jeil Pharm and SK Chemicals had their Hemlibra subcutaneous injection, Lonsurf tablet and Ongentis capsule approved, respectively, but all of them were developed from abroad. K-CAB tablet (tegoprazan, CJ Health Care), approved on July 5, 2018, is still the latest Korean-made new drug. 2019 new drugs Out of all drugs approved last year, five were biological drugs and 17 were synthetic drugs. MFDS has approved two IMDs last year, including; an amlodipine besylate-chlorthalidone-telmisartan triple combination drug, True Set tablet (Yuhan), and eight items of multiple combination drugs with pitavastatin calcium and fenobirate. Besides, three biosimilars—Samsung Bioepis’ Etolce 50 mg prefilled syringe (etanercept), Daewon Pharmaceutical’s Terosa cartridge injection and Pangen’s Panpotin prefilled syringe injection—were approved last year as well. Meanwhile, total 4,793 finished pharmaceutical products (661 OTC, 4,132 prescription drugs) have been approved last year. Compared to 2,056 products approved in 2018, year 2019 had significantly more finished products cleared. The surge in approved finished products could have been because of surge in number of CMO-manufactured generics with cosigned bioequivalence test. 4,207 generics have been cleared in 2019, which the number doubled from 1,754 in 2018. Sources analyze it was because many of the generics have applied for approval in a hurry before the cosigned bioequivalence test limiting policy came into effect.
- Policy
- Ibrutinib's Asian Standard Therapy Strategy Revealed
- by Lee, Jeong-Hwan Jan 10, 2020 06:24am
- A domestic study shows that allogeneic hematopoietic stem cell transplantation is the ultimate treatment strategy for patients who do not have treatment effect after 3 months after taking Imbruvica (Ibrutinib/Janssen), a kind of hematologic cancer. The researchers also found that the initial prognostic factors of mantle cell lymphoma and the failure to treat early Ibrutinib were a poor risk factor for refractory and recurrent mantle lymphoma. The Korean researchers have suggested a standardized treatment strategy for applying target anticancer drugs in mantle cell lymphoma disease. On the 8th, the research team of Professor Seok-gu Cho and Young-woo Jeon of the Lymphoma Center, Yeouido St. Mary's Hospital, Catholic University, Korea, released the findings. The new drug Ibrutinib is an oral capsule and is a special anticancer drug that kills only cancer cells. It is effective in some patients with lymphoma and attracts attention as a new treatment. Therapeutic research has been difficult for 'relapsed and non-refractory mantle cell lymphoma', which accounts for 6% of non-Hodgkin's lymphoma patients. In particular, the price of new drugs, such as Imbrica, was so expensive that accessibility to patients was low. This is why it is meaningful that a team of professors Seok-gu Cho and Young-woo Jeon at the Yeouido St. Mary's Hospital Lymphoma Center of Catholic University apply a single treatment at a single institution and analyze the Ibrutinib treatment response in the same patient. For four years (2013-2018), the researchers collected patient groups from the Lymphoma-myeloma center of the Seoul St. Mary's Hospital, and the Lymphoma Center of the Yeouido St. Mary's Hospital. Thirty-three patients who were prescribed Ibrutinib for recurrence of disease during the use of R-CHOP, a representative primary treatment, after the diagnosis of mantle cell lymphoma. The team analyzed the effects of Ibrutinib treatment and predictive outcomes. The disease-free survival of patients with refractory and recurrent mantle lymphoma with Ibrutinib was about 35 months, longer than the control group, 12 months. Based on the response for 3 months after taking Ibrutinib, the disease-free survival rate was also classified into ▲ early treatment response group and early treatment failure group. The disease-free survival rate was 82% in the early treatment responders with complete or partial remission and 18% in the early failure groups. The early treatment response group was found to maintain long-term survival while maintaining remission, but the early treatment failure group died within six months. The team found a risk factor that predicted a poor prognosis for patients with refractory and recurrent mantle cell lymphoma. ▲The initial prognostic factors of mantle cell lymphoma at first visit were poor, or ▲The initial treatment failed after taking Ibrutinib. It was also confirmed that allogeneic hematopoietic stem cell transplantation was the ultimate treatment for patients who had no therapeutic effect on Iburitinib. Professor Seok-gu Cho (corresponding author) said, "Cortic cell lymphoma is a disease with a very low incidence and a poor recurrence, and the new drug-targeted anticancer drug study is meaningful to patients who relapse during treatment with established and consistent treatments". Professor Cho added, "It also means that the analysis of prognostic factors and prognostic factors for the new drug-targeted anticancer drug is the initial analysis data published for Asians". Professor Jeon Young-woo, the first author, said, “New drug Ibrutinib is not a perfect treatment. Rapidity is most important in treating lymphoma when deciding and switching treatment, and the prognosis is extremely poor. A strategy to improve survival by allogeneic hematopoietic stem cell transplantation is important, and the study was published in the September 2019 issue of Cancer Medicin (IF = 3.35)”.
